Journal article

The Balance between the Safety of Mother, Fetus, and Newborn Undergoing Cystic Fibrosis Transmembrane Conductance Regulator Treatments during Pregnancy

Fiona Qiu, Mark Habgood, Elena K Schneider-Futschik

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE | AMER CHEMICAL SOC | Published : 2020

Abstract

The recent development of modulators of cystic fibrosis transmembrane conductance regulator (CFTR) has allowed the life expectancy of cystic fibrosis patients to increase substantially resulting in more women with cystic fibrosis reaching child-bearing age. This however raises the issue of whether long-term use of CFTR modulators during pregnancy and breastfeeding is safe for the fetus and newborn, especially for their developing brain. A very limited number of case reports available so far has shown that the fetus or breastfed newborn is likely to be exposed to maternally administered CFTR modulators. Potential impacts of drug exposure on the developing brain are of particular importance as..

View full abstract

Grants

Funding Acknowledgements

E.K.S.-F. is supported by a research grant from The University of Melbourne and the Australian National Health and Medical Research Council (NHMRC) as Biomedical Research Fellow. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Australian National Health and Medical Research Council. The authors thank A/Prof. Katarzyna Dziegielewska, AM, and Prof. Norman Saunders, AM (University of Melbourne), for technical assistance, guidance, and mentorship.